These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

712 related articles for article (PubMed ID: 35228114)

  • 1. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
    Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
    Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
    Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
    JAMA Neurol; 2018 Mar; 75(3):320-327. PubMed ID: 29309484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017.
    Vermersch P; Suchet L; Colamarino R; Laurendeau C; Detournay B
    Mult Scler Relat Disord; 2020 Nov; 46():102521. PubMed ID: 32977077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
    Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
    J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.
    Freeman L; Longbrake EE; Coyle PK; Hendin B; Vollmer T
    CNS Drugs; 2022 Dec; 36(12):1285-1299. PubMed ID: 36350491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.
    Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
    J Neurol; 2021 Mar; 268(3):941-949. PubMed ID: 32974794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
    Diouf I; Malpas CB; Sharmin S; Roos I; Horakova D; Kubala Havrdova E; Patti F; Shaygannejad V; Ozakbas S; Eichau S; Onofrj M; Lugaresi A; Alroughani R; Prat A; Duquette P; Terzi M; Boz C; Grand'Maison F; Sola P; Ferraro D; Grammond P; Yamout B; Altintas A; Gerlach O; Lechner-Scott J; Bergamaschi R; Karabudak R; Iuliano G; McGuigan C; Cartechini E; Hughes S; Sa MJ; Solaro C; Kappos L; Hodgkinson S; Slee M; Granella F; de Gans K; McCombe PA; Ampapa R; van der Walt A; Butzkueven H; Sánchez-Menoyo JL; Vucic S; Laureys G; Sidhom Y; Gouider R; Castillo-Trivino T; Gray O; Aguera-Morales E; Al-Asmi A; Shaw C; Al-Harbi TM; Csepany T; Sempere AP; Treviño Frenk I; Stuart EA; Kalincik T
    J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):1004-1011. PubMed ID: 37414534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
    Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
    BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
    Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
    J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
    Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Van Der Walt A; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Blanco Morgado Y; Spitaleri D; van Pesch V; Horakova D; Ampapa R; Patti F; Macdonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H
    Mult Scler; 2023 Feb; 29(2):221-235. PubMed ID: 36433775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness and safety of ozanimod
    Paul D; Swallow E; Patterson-Lomba O; Branchcomb T; N'Dri L; Gomez-Lievano A; Liu J; Dua A; McGinley M
    Ther Adv Neurol Disord; 2024; 17():17562864241237856. PubMed ID: 38855023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
    Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
    Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Patient and Clinician Assessment of Gastrointestinal (GI) Related Adverse Events Associated with Oral Disease-Modifying Therapies in Multiple Sclerosis: A Qualitative Study.
    Jivraj F; Kang S; Reedie S; Kapadia S; Strzok S; Elliott E; Cano S; Rock M
    Adv Ther; 2022 Nov; 39(11):5072-5086. PubMed ID: 36053450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.
    Zhu C; Kalincik T; Horakova D; Zhou Z; Buzzard K; Skibina O; Alroughani R; Izquierdo G; Eichau S; Kuhle J; Patti F; Grand'Maison F; Hodgkinson S; Grammond P; Lechner-Scott J; Butler E; Prat A; Girard M; Duquette P; Macdonell RAL; Weinstock-Guttman B; Ozakbas S; Slee M; Sa MJ; Van Pesch V; Barnett M; Van Wijmeersch B; Gerlach O; Prevost J; Terzi M; Boz C; Laureys G; Van Hijfte L; Kermode AG; Garber J; Yamout B; Khoury SJ; Merlo D; Monif M; Jokubaitis V; van der Walt A; Butzkueven H;
    JAMA Neurol; 2023 Jul; 80(7):739-748. PubMed ID: 37273217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry.
    Stuchiner T; Lucas L; Baraban E; Spinelli KJ; Chen C; Smith A; Hashemi L; Cohan S
    BMC Neurol; 2020 Dec; 20(1):439. PubMed ID: 33272224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies.
    Duquette P; Yeung M; Mouallif S; Nakhaipour HR; Haddad P; Schecter R
    PLoS One; 2019; 14(1):e0210417. PubMed ID: 30640935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-life outcomes for oral disease-modifying treatments of relapsing-remitting multiple sclerosis patients: Adherence and adverse event profiles from Marmara University.
    Vural E; Engin E; Sünter G; Yıldırım KA; Günal D
    Turk J Med Sci; 2023 Jun; 53(3):771-779. PubMed ID: 37476900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis.
    Hou J; Kim N; Cai T; Dahal K; Weiner H; Chitnis T; Cai T; Xia Z
    JAMA Netw Open; 2021 Nov; 4(11):e2134627. PubMed ID: 34783826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
    Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register.
    Zanghì A; Avolio C; Amato MP; Filippi M; Trojano M; Patti F; Amico E;
    Mult Scler Relat Disord; 2022 Feb; 58():103489. PubMed ID: 35032879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.